Your browser is no longer supported. Please, upgrade your browser.
GILD Gilead Sciences, Inc. weekly Stock Chart
GILD [NASD]
Gilead Sciences, Inc.
IndexS&P 500 P/E- EPS (ttm)-0.24 Insider Own0.41% Shs Outstand1.26B Perf Week-0.92%
Market Cap84.86B Forward P/E9.68 EPS next Y7.04 Insider Trans-1.19% Shs Float1.25B Perf Month-11.05%
Income-257.00M PEG- EPS next Q1.98 Inst Own82.40% Short Float1.77% Perf Quarter-11.72%
Sales22.17B P/S3.83 EPS this Y1.10% Inst Trans-0.31% Short Ratio2.27 Perf Half Y2.07%
Book/sh14.36 P/B4.75 EPS next Y0.79% ROA-0.40% Target Price80.17 Perf Year8.02%
Cash/sh15.20 P/C4.49 EPS next 5Y2.27% ROE-1.20% 52W Range60.89 - 85.97 Perf YTD4.92%
Dividend2.72 P/FCF16.40 EPS past 5Y-10.50% ROI9.50% 52W High-20.62% Beta0.62
Dividend %3.99% Quick Ratio2.20 Sales past 5Y-2.00% Gross Margin78.60% 52W Low12.07% ATR1.56
Employees11800 Current Ratio2.30 Sales Q/Q-9.50% Oper. Margin-4.30% RSI (14)35.30 Volatility1.59% 2.04%
OptionableYes Debt/Eq1.34 EPS Q/Q-280.70% Profit Margin-1.20% Rel Volume0.35 Prev Close68.18
ShortableYes LT Debt/Eq1.17 EarningsJul 30 AMC Payout- Avg Volume9.71M Price68.24
Recom2.50 SMA20-5.51% SMA50-8.22% SMA200-4.46% Volume188,877 Change0.09%
Jul-31-20Reiterated Wells Fargo Equal Weight $87 → $76
Jul-31-20Reiterated SunTrust Hold $73 → $74
Jul-31-20Reiterated RBC Capital Mkts Outperform $89 → $87
Jul-31-20Reiterated Piper Sandler Overweight $90 → $85
Jul-31-20Reiterated Morgan Stanley Equal-Weight $80 → $79
Jul-31-20Reiterated Credit Suisse Neutral $75 → $73
Jul-20-20Upgrade Credit Suisse Underperform → Neutral $64 → $75
Jun-03-20Upgrade SVB Leerink Mkt Perform → Outperform $85 → $94
May-26-20Upgrade SunTrust Sell → Hold $73
May-01-20Downgrade SunTrust Hold → Sell $70
May-01-20Downgrade Raymond James Outperform → Mkt Perform
May-01-20Downgrade JP Morgan Overweight → Neutral
Apr-27-20Downgrade UBS Buy → Neutral $77 → $80
Apr-20-20Downgrade Wells Fargo Overweight → Equal Weight $87
Apr-20-20Downgrade BMO Capital Markets Outperform → Market Perform $79
Apr-17-20Downgrade CFRA Hold → Sell
Mar-31-20Initiated Wolfe Research Peer Perform
Mar-20-20Upgrade Piper Sandler Neutral → Overweight $70 → $90
Mar-18-20Upgrade DZ Bank Hold → Buy $80
Mar-09-20Downgrade RBC Capital Mkts Top Pick → Outperform $86
Aug-13-20 05:19PM  
12:16AM  
Aug-12-20 02:35PM  
12:23PM  
08:25AM  
08:21AM  
Aug-11-20 05:05PM  
10:28AM  
08:11AM  
01:34AM  
Aug-10-20 03:11PM  
02:33PM  
11:55AM  
11:11AM  
11:06AM  
11:00AM  
08:38AM  
07:06AM  
Aug-09-20 07:00AM  
Aug-07-20 04:23PM  
12:02PM  
11:04AM  
10:07AM  
09:11AM  
08:10AM  
08:07AM  
04:00AM  
Aug-06-20 04:05PM  
Aug-05-20 07:58AM  
02:00AM  
Aug-04-20 10:09PM  
01:35PM  
11:45AM  
06:41AM  
04:26AM  
Aug-03-20 12:46PM  
05:45AM  
Aug-01-20 10:44AM  
01:33AM  
Jul-31-20 06:51PM  
06:33PM  
04:43PM  
04:35PM  
04:31PM  
12:56PM  
11:35AM  
10:30AM  
08:45AM  
06:34AM  
Jul-30-20 11:31PM  
07:28PM  
06:43PM  
05:15PM  
05:14PM  
04:28PM  
04:11PM  
04:02PM  
04:01PM  
10:14AM  
06:30AM  
Jul-29-20 05:21PM  
04:28PM  
01:42PM  
12:25PM  
09:27AM  
07:00AM  
06:11AM  
Jul-28-20 10:57AM  
09:00AM  
Jul-27-20 06:07PM  
02:50PM  
01:31PM  
03:38AM  
Jul-26-20 08:16AM  
Jul-25-20 08:06AM  
Jul-24-20 04:57PM  
01:25PM  
01:12PM  
11:38AM  
08:49AM  
08:33AM  
08:10AM  
06:51AM  
Jul-23-20 02:35PM  
12:32PM  
11:02AM  
10:14AM  
Jul-22-20 09:37AM  
Jul-21-20 04:02PM  
01:21PM  
10:00AM  
09:57AM  
08:43AM  
08:30AM  
08:24AM  
07:01AM  
Jul-20-20 05:45PM  
12:25PM  
11:38AM  
Jul-19-20 09:00AM  
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a kinase inhibitor; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections. In addition, the company offers its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. Further, it develops product candidates for the treatment of viral diseases, inflammatory and fibrotic diseases, and oncology. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Second Genome; Gadeta; Carna Biosciences Inc.; Nurix Therapeutics, Inc.; Humanigen, Inc.; Kiniksa Pharmaceuticals, Ltd.; Kyverna Therapeutics, Inc.; Glympse Bio, Inc.; Renown Institute for Health Innovation; Goldfinch Bio, Inc.; Insitro, Inc.; Novo Nordisk A/S; Yuhan Corporation; Kite Pharma, Inc.; oNKo-innate Pty. Ltd.; and Roche Holding AG. The company has partnership with Arcus Biosciences, Inc. to co-develop and co-commercialize next-generation cancer immunotherapies. Gilead Sciences, Inc. was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Mercier JohannaChief Commercial OfficerJul 24Option Exercise0.007,50507,505Jul 28 06:47 PM
Rodriguez JavierDirectorJun 23Sale75.5018914,2700Jun 25 01:51 PM
Dickinson Andrew DEVP, Chief Financial OfficerJun 10Option Exercise0.003,646015,046Jun 12 03:28 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselMay 05Option Exercise39.7613,210525,22527,854May 07 06:02 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselMay 05Sale79.2313,2101,046,64014,644May 07 06:02 PM
Cogan John FrancisDirectorMay 04Option Exercise19.632,41647,42657,276May 05 04:28 PM
Wilfong Diane E.SVP, Controller & CAOMay 04Option Exercise66.3611,486762,21123,685May 06 06:40 PM
Wilfong Diane E.SVP, Controller & CAOMay 04Sale80.0912,264982,22011,421May 06 06:40 PM
Cogan John FrancisDirectorMay 04Sale81.752,416197,50854,860May 05 04:28 PM
Cogan John FrancisDirectorApr 27Option Exercise19.632,41347,36757,273Apr 29 07:28 PM
Cogan John FrancisDirectorApr 27Sale79.902,413192,79954,860Apr 29 07:28 PM
Cogan John FrancisDirectorApr 20Option Exercise19.632,41347,36757,273Apr 21 07:42 PM
Cogan John FrancisDirectorApr 20Sale83.002,413200,27954,860Apr 21 07:42 PM
Cogan John FrancisDirectorApr 13Option Exercise19.632,41347,36757,273Apr 14 03:52 PM
Cogan John FrancisDirectorApr 13Sale75.902,413183,14754,860Apr 14 03:52 PM
Cogan John FrancisDirectorApr 06Option Exercise19.632,41347,36757,273Apr 07 05:34 PM
Cogan John FrancisDirectorApr 06Sale79.522,413191,88254,860Apr 07 05:34 PM
Cogan John FrancisDirectorMar 30Option Exercise19.632,41347,36757,273Mar 31 03:00 PM
Cogan John FrancisDirectorMar 30Sale75.352,413181,82054,860Mar 31 03:00 PM
Cogan John FrancisDirectorMar 23Option Exercise19.632,41347,36757,273Mar 24 08:42 PM
Cogan John FrancisDirectorMar 23Sale75.272,413181,62754,860Mar 24 08:42 PM
Cogan John FrancisDirectorMar 16Option Exercise19.632,41347,36757,273Mar 17 08:01 PM
Cogan John FrancisDirectorMar 16Sale67.262,413162,29854,860Mar 17 08:01 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselMar 10Option Exercise24.302,95071,67017,594Mar 12 08:30 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselMar 10Sale75.552,950222,87314,644Mar 12 08:30 PM
Cogan John FrancisDirectorMar 09Option Exercise19.632,41347,36757,273Mar 10 09:16 PM
Cogan John FrancisDirectorMar 09Sale77.972,413188,14254,860Mar 10 09:16 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselMar 02Sale70.8810,441740,01414,644Mar 03 07:40 PM
Lofton Kevin EDirectorFeb 24Option Exercise19.6321,720426,36486,579Feb 25 05:13 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselFeb 10Option Exercise24.302,95071,67027,640Feb 12 06:25 PM
WILSON GAYLE EDirectorFeb 10Option Exercise19.6321,720426,364148,502Feb 11 07:02 PM
WILSON GAYLE EDirectorFeb 10Sale67.7221,7201,470,878126,782Feb 11 07:02 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselFeb 10Sale69.322,950204,49424,690Feb 12 06:25 PM
WOLD OLSEN PERDirectorFeb 07Option Exercise20.6520,282418,722118,136Feb 10 06:25 PM
WOLD OLSEN PERDirectorFeb 07Sale69.0020,2821,399,45897,854Feb 10 06:25 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselFeb 07Sale70.001,42699,82024,690Feb 10 07:00 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselFeb 06Option Exercise40.565,000202,80029,690Feb 10 07:00 PM
WOLD OLSEN PERDirectorFeb 06Option Exercise19.6321,720426,364119,574Feb 10 06:25 PM
WOLD OLSEN PERDirectorFeb 06Sale68.1221,7201,479,60597,854Feb 10 06:25 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselFeb 06Sale68.185,000340,90124,690Feb 10 07:00 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselJan 03Option Exercise24.302,95071,67020,014Jan 06 07:01 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselJan 03Sale64.632,950190,65917,064Jan 06 07:01 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselDec 03Option Exercise24.305,900143,34122,964Dec 04 07:11 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselDec 03Sale65.775,900388,04317,064Dec 04 07:11 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselNov 25Option Exercise40.5615,000608,40032,064Nov 26 02:14 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselNov 25Sale66.8515,0001,002,80917,064Nov 26 02:14 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselNov 19Option Exercise24.3010,000242,95027,064Nov 20 06:11 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselNov 19Sale64.9110,000649,06217,064Nov 20 06:11 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselNov 18Option Exercise24.3010,000242,95027,064Nov 20 06:11 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselNov 18Sale63.8510,000638,50017,064Nov 20 06:11 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselNov 05Sale66.062,095138,40417,826Nov 07 08:04 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselNov 01Option Exercise16.892,40040,53623,921Nov 05 08:21 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselNov 01Sale64.524,000258,09919,921Nov 05 08:21 PM
Pletcher Brett AEVP, Gen Counsel & Corp SecOct 28Sale63.315,677359,41221,521Oct 30 08:35 PM
Lofton Kevin EDirectorOct 01Option Exercise0.0021,527064,859Oct 03 09:03 PM
WOLD OLSEN PERDirectorAug 28Option Exercise23.764,908116,590102,762Aug 29 04:42 PM
WOLD OLSEN PERDirectorAug 28Sale63.914,908313,67197,854Aug 29 04:42 PM
Pletcher Brett AEVP, Gen Counsel & Corp SecAug 19Sale64.3560839,12327,198Aug 20 03:13 PM